JP Morgan Chase
LGND icon

JP Morgan Chase’s Ligand Pharmaceuticals LGND Stock Holding History

JP Morgan Chase’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,412
Closed -$357K – 6676
2022
Q2 		$357K Buy
+6,412
New +$364K ﹤0.01% 4755
2020
Q2 		– Sell
-3,527
Closed -$160K – 5550
2020
Q1 		$160K Buy
+3,527
New +$200K ﹤0.01% 4356
2019
Q1 		– Sell
-561,050
Closed -$47.5M – 5921
2018
Q4 		$47.5M Buy
+561,050
New +$59.8M 0.01% 920
2017
Q2 		– Sell
-43,281
Closed -$2.86M – 5091
2017
Q1 		$2.86M Sell
43,281
-24,045
-36% -$1.58M ﹤0.01% 2813
2016
Q4 		$4.27M Buy
+67,326
New +$4.25M ﹤0.01% 2580

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

JP Morgan Chase's LGND Position: Q1 2026 in Review

JP Morgan Chase increased its Ligand Pharmaceuticals (LGND) stake by 52% in Q1 2026, buying an estimated $5.87M and bringing the position to 86,274 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

JP Morgan Chase first reported a position in LGND in Q2 2013 and has held it in 45 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • JP Morgan Chase held 86,274 shares of Ligand Pharmaceuticals worth $16.6M as of Q1 2026.
  • JP Morgan Chase bought 29,684 Ligand Pharmaceuticals shares in Q1 2026, an estimated $5.87M.
  • Ligand Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2235 holding.
  • JP Morgan Chase first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.